RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
Open original sourceLoading market dashboard
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.
Open original source